BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 21993994)

  • 21. α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration.
    Tang Y; Thiess L; Weiler SME; Tóth M; Rose F; Merker S; Ruppert T; Schirmacher P; Breuhahn K
    Cell Commun Signal; 2023 Jun; 21(1):162. PubMed ID: 37381005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Akt and mTORC1 have different roles during liver tumorigenesis in mice.
    Kenerson HL; Yeh MM; Kazami M; Jiang X; Riehle KJ; McIntyre RL; Park JO; Kwon S; Campbell JS; Yeung RS
    Gastroenterology; 2013 May; 144(5):1055-65. PubMed ID: 23376645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma.
    Ribback S; Che L; Pilo MG; Cigliano A; Latte G; Pes GM; Porcu A; Pascale RM; Li L; Qiao Y; Dombrowski F; Chen X; Calvisi DF
    Cell Cycle; 2018; 17(12):1496-1512. PubMed ID: 29965794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
    Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer.
    Chand V; Pandey A; Kopanja D; Guzman G; Raychaudhuri P
    Mol Cancer Res; 2019 May; 17(5):1063-1074. PubMed ID: 30814128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of targeting Notch receptors in a mouse model of liver cancer.
    Huntzicker EG; Hötzel K; Choy L; Che L; Ross J; Pau G; Sharma N; Siebel CW; Chen X; French DM
    Hepatology; 2015 Mar; 61(3):942-52. PubMed ID: 25311838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
    Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
    Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer.
    Tao J; Ji J; Li X; Ding N; Wu H; Liu Y; Wang XW; Calvisi DF; Song G; Chen X
    Oncotarget; 2015 Mar; 6(9):6977-88. PubMed ID: 25762642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice.
    Wu H; Tao J; Li X; Zhang T; Zhao L; Wang Y; Zhang L; Xiong J; Zeng Z; Zhan N; Steer CJ; Che L; Dong M; Wang X; Niu J; Li Z; Yan G; Chen X; Song G
    Hepatology; 2017 Dec; 66(6):1952-1967. PubMed ID: 28714063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
    Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
    Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress.
    Thompson SM; Callstrom MR; Jondal DE; Butters KA; Knudsen BE; Anderson JL; Lien KR; Sutor SL; Lee JS; Thorgeirsson SS; Grande JP; Roberts LR; Woodrum DA
    PLoS One; 2016; 11(9):e0162634. PubMed ID: 27611696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis.
    Lee SA; Ladu S; Evert M; Dombrowski F; De Murtas V; Chen X; Calvisi DF
    Hepatology; 2010 Aug; 52(2):506-17. PubMed ID: 20683950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression.
    Hu G; Yan Z; Zhang C; Cheng M; Yan Y; Wang Y; Deng L; Lu Q; Luo S
    J Exp Clin Cancer Res; 2019 May; 38(1):188. PubMed ID: 31072351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways.
    Wang C; Delogu S; Ho C; Lee SA; Gui B; Jiang L; Ladu S; Cigliano A; Dombrowski F; Evert M; Calvisi DF; Chen X
    J Hepatol; 2012 Sep; 57(3):577-83. PubMed ID: 22617155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice.
    Hartwell HJ; Petrosky KY; Fox JG; Horseman ND; Rogers AB
    Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11455-60. PubMed ID: 25049387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.